Jounce Therapeutics to Present at Upcoming Investor Conferences in March
February 26 2020 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Jounce management will present at two upcoming investor
conferences:
- Cowen & Co. 40th Annual Health Care
Conference at 10:00 a.m. ET on Wednesday, March 4, 2020 in
Boston, MA
- 32nd Annual ROTH Conference at 1:00 p.m. PT on
Tuesday, March 17, 2020 in Orange County, CA
A live webcast of each presentation will be available by
visiting “Events and Presentations” in the Investors and Media
section of Jounce’s website at www.jouncetx.com. A replay of each
webcast will be archived for 30 days following the
presentations.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
has three development-stage programs, two of which are
clinical-stage, vopratelimab, a monoclonal antibody that binds to
and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for
combination use with Jounce’s broader pipeline. Vopratelimab is
currently being assessed in a Phase 2 clinical trial, EMERGE, and a
biomarker trial using TISvopra for patient selection, SELECT, to
assess vopratelimab in combination with JTX-4014 will be initiated
mid-year 2020. The next development candidate to emerge from
Jounce’s Translational Science Platform is JTX-1811, a monoclonal
antibody designed to selectively deplete T regulatory cells in the
tumor microenvironment. JTX-1811 is currently in IND-enabling
activities. In addition, Jounce has exclusively licensed worldwide
rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene
Corporation, a wholly-owned subsidiary of Bristol-Myers Squibb
Company. For more information, please visit www.jouncetx.com.
Investor and Media Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024